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Abstract
We describe a novel, testable theory of autoimmunity, outline novel predictions made by the theory, and illustrate its
application to unravelling the possible causes of idiopathic thrombocytopenia purpura (ITP). Pairs of stereochemically
complementary antigens induce complementary immune responses (antibody or T-cell) that create loss of regulation and civil
war within the immune system itself. Antibodies attack antibodies creating circulating immune complexes; T-cells attack
T-cells creating perivascular cufﬁng. This immunological civil war abrogates the self–nonself distinction. If at least one of
the complementary antigens mimics a self antigen, then this unregulated immune response will target host tissues as well.
Data demonstrating that complementary antigens are found in some animal models of autoimmunity and may be present in
various human diseases, especially ITP, are reviewed. Speciﬁc mechanisms for preventing autoimmunity or suppressing
existing autoimmunity are derived from the theory, and critical tests proposed. Finally, we argue that Koch’s postulates are
inadequate for establishing disease causation for multiple-antigen diseases and discuss the possibility that current research has
failed to elucidate the causes of human autoimmune diseases because we are using the wrong criteria.
Keywords: Circulating immune complexes, complementary antigens, idiotype–antiidiotype, ITP, Koch’s postulates, theory of
autoimmunity
Introduction
The origins of human autoimmune diseases remain
one of the outstanding mysteries of modern medicine.
Standard textbook accounts attribute induction of
autoimmunity to one of ﬁve, non-exclusive, processes:
(1) molecular mimicry between foreign antigens and
“self” determinants that results in cross-reactivity
of idiotypic antibodies with the “self” determinants;
(2) induction of anti-idiotypic antibodies that cross-
react with “self” determinants following a normal
idiotypic response to a foreign antigen; (3) release of
sequestered or “hidden” alloantigens that activate an
active immune response; (4) incomplete clonal
deletion, which leaves auto-reactive T- or B-cell clones
available for activation by foreign antigens; (5) genetic
predisposition to autoimmunity. While some evidence
exists to support each of these processes, no coherent
theory of autoimmunity that integrates all available
observations exists, nor have any of the current
theories led to the development of autoimmune
disease models in animals that reproduce naturally
occurring processes of autoimmunity induction. This
paper attempts to provide an integrated, testable
theory of autoimmune disease induction that provides
strategies for identifying infectious agents involved in
disease induction. We demonstrate the manner in
which the theory can be applied and tested with regard
to idiopathic thrombocytopenia purpura (ITP).
Theory
The theory presented here posits a process that can
break “self” tolerance by confusing the immune
system itself. The process involves provoking the
immune system with a pair of molecularly comple-
mentary antigens (at least one of which mimics a
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complementary immune responses that attack each
other as well as a tissue or organ within the body
(Figure 1). The theory asserts that pairs of comple-
mentary antigens will be processed differently than
individual or non-complementary sets of antigens.
(Westall and Root-Bernstein 1983a,b, 1986, Root-
Bernstein and Westall 1986, Root-Bernstein 1991a,b)
Consider the immunological processing of individ-
ual antigens ﬁrst. In a typical immune response, each
antigen elicits a complementary antibody or T-cell
response. These antibody or T-cell responses are
independently controlled and non-interactive. Anti-
gens that too closely mimic “self” determinants will
not induce an immune response. The immune system
down-regulates its activity against each antigen as that
antigen is eliminated from the body.
Complementary antigens will be processed quite
differently than individual antigens or sets of non-
complemenatry antigens. Complementary antigens
will form a molecular complex that is antigenically
unique. While each component of such a molecular
complex may mimic a “self” determinant, the
complex itself will have a unique structure that does
not. Thus, the complex will be antigenic even if the
components individually would be too similar to
“self” determinants to be antigenic. Subsequent
processing of the complex results in a range of
antibodies or T-cell reactive clones, some primarily
against the antigenic complex, some biased towards
components of the complex. It is the immunological
response against self-mimicking components of the
complex that result in autoimmune processes.
The results of simultaneously immunologically
processing a pair of complementary antigens will
result initially in abrogation of the self–nonself
distinction within the immune system itself
(Figure 1). To begin with, immunological response
to one antigen will result in antibodies (or T-cells)
complementary to that ﬁrst antigen, which will mimic
stereochemically the second, complementary antigen.
Similarly, the immunological response to the second
antigen will result in antibodies (or T-cells) comple-
mentary to the second antigen, which will mimic
stereochemically the ﬁrst, complementary antigen.
Thus, each immunological response will mimic one of
the antigens. Since the antigens are complementary,
the immunological responses will also be comple-
mentary so that the resulting antibodies (or T-cells)
will attack each other. Thus, while each antibody (or
T-cell) response is “self”, each response will be viewed
by the immune system as also being “non-self”.
Immunological tolerance will thereby be broken, and
each immune response will continuously provoke its
complementary response in an unending cycle of
immunological civil war.
At heart, then, this theory proposes that all
autoimmune diseases begin as autoimmune responses
within and against the immune system itself. Intra-
immunological warfare can spread to other tissues or
organs if at least one of the pair of complementary
antigens mimics a “self” determinant. In these
circumstances, the “self” determinant will also
become a target of the now unregulated immune
response and provide an essentially continuous
stimulus to this response.
Figure 1. Schematic model of the complementary antigen theory of autoimmunity. If a pair of antigens are molecularly or stereochemically
complementary (as deﬁned by their ability to bind to each other speciﬁcally) then they will induce molecularly complementary antibody (or
T-cell) responses), i.e. having an idiotype–antiidiotype relationship—but both antibodies will be idiotypic. These complementary antibodies
will bind to each other and their respective antigens to create circulating immune complexes. Each antibody will also treat the other as
“nonself” and therefore the self–nonself distinction will be abrogated and an immunological civil war initiated. If one or both of the antigens
are molecular mimics of a self determinant, then this unregulated immunological civil war will spread to attack host tissues or organs. The
same basic mechanism will occur in T-cell mediated autoimmune diseases as well.
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upon, Jerne’s network theory of immunological
regulation (Steinberg and Lefkovits 1981). One can
reinterpret the description given above in terms of
idiotypes and antiidiotypes. A complementary pair of
antigens will induce a pair of idiotypic immunological
responses that behave as if they were idiotypic–
antiidiotypic pairs. If one assumes that regulation of
immunological responses requires a cascade of
idiotype–antiidiotype responses, as Jerne’s theory
does, then inducing a pair of simultaneous primary
idiotypic immunological responses that act as anti-
idiotypic responses for each other destroys network
regulation. In fact, antiidiotypic immune responses
have been characterized in a wide range of auto-
immune diseases including ITP, diabetes and AIDS
(e.g. Shoelson et al. 1986, Balint and Jones 1994,
Silvestris et al. 1994, Krook et al. 1996, Nardi and
Karpatkin 2000). It is worth bearing in mind that
these immune responses may not, in fact, be
antiidiotypic, but primary idiotypic responses that
result from a pair of complementary antigens. More
on this point in the next section.
Predictions made by the theory
The antigenic complementarity theory of autoimmun-
ity makes testable predictions. One is that complexes
of complementary antigens should be able to induce
experimental autoimmune diseases.Two cases suggest
that this is correct.
It has been demonstrated in studies of experimental
allergic encephalomyelitis (EAE) that the minimal
components necessary to induce the disease in guiniea
pigs are a combination of the tryptophan peptide of
myelin basic protein (EAE peptide) and muramyl
dipeptide (MDP), a fragment of bacterial cell walls
(Westall and Root-Bernstein 1983a,b, 1986, Root-
Bernstein 1991b). Westall and Root-Bernstein have
demonstrated using nuclear magnetic resonance
spectroscopy and other techniques that EAE peptide
has a binding site for MDP and that the two molecules
bind to each other to form a stable complex (Root-
Bernstein and Westall 1983, 1990, Takeuchi et al.
1990). It has also been demonstrated that insulin
binds to glucagon to form a stable complex that is
hyperantigenic (Root-Bernstein and Dobbelstein
2001). Moreover, all antibodies supposedly induced
by insulin, whether in experimental animals or human
patients with diabetes, have signiﬁcantly higher
afﬁnity for an insulin–glucagon complex than for
insulin alone (Root-Bernstein and Dobbelstein 2001).
These data suggest that in experimental auto-
immune diseases such as autoimmune thyroiditis that
are currently induced using a combination of a self-
mimicking protein “antigen” (thyroglobulin) and a
complex bacterial “adjuvant” (lipopolysaccharide or
Freund’s complete adjuvant) (e.g. Esquivil et al.
1977), a pair of complementary, binding antigens will
be isolatable as the minimal necessary inducers of
autoimmunity. In cases involving the use of complex
antigen mixtures for the induction of autoimmune
models, such as that of mycobacterial-induced
adjuvant arthritis, the complementary antigen theory
predicts that the minimal components will consist of a
pair of antigens from the mixture. This prediction is
given some credibility from the fact that no single
chemical component of mycobacteria has yet been
found to be able to induce adjuvant arthritis by itself
and puriﬁed components (e.g. heat shock proteins and
collagens) can be used to vaccinate against adjuvant
arthritis (Billingham et al. 1990, Zhang et al. 1990,
Yang et al. 1992, Prakken et al. 1997, Ulmansky et al.
2002). The current theory proposes that a minimum
of two mycobacterial antigens having a comple-
mentary relationship will be found to be necessary to
induce adjuvant arthritis.
A second major prediction made by the comple-
mentary antigen theory is that circulating immune
complexes and perivascular cuffs or other immuno-
logical aggregates are results of complementary
immune responses. Circulating immune complexes
are highly associated with autoimmune disease
(Clancy et al. 1980, Trent et al. 1980, Puram et al.
1984, Morrow et al. 1986, Kurata et al. 1987, Reddy
and Grieco 1990, Stanojevic et al. 1996). In antibody-
mediated forms of autoimmunity, CIC will be found
to be composed not only of antibody–antigen
aggregates, as standard research and textbook
descriptions maintain, but also of antibody–antibody
aggregates (Figure 1). Similarly, perivascular cuffs or
other lymphocyte aggregates in cell-mediates auto-
immune diseases will be found to be composed of
complementary sets of lymphocytes that are able to
bind to, and attack, each other (Root-Bernstein
1991b).
A third prediction of the theory is that post-
infectious and post-vaccinal autoimmune diseases
should occur most frequently in individuals who have
speciﬁc pairs of concurrent, combined infections (or
vaccinations superimposed upon an appropriate active
infection), in which complementary antigens are
present. If the theory is correct, then the more
chronic, concurrent infections an individual develops,
or the larger the number of distinct antigens
encountered simultaneously (as in multiple vacci-
nation programs for soldiers going overseas) the
greater will be their probability of contracting a pair of
complementary antigens that mimic one or more
“self” determinants. People with AIDS are prototypes
for this scenario and, indeed, they develop all forms of
autoimmunity at hundreds of times the rate found
in the general population (Morrow et al. 1991,
Zandman-Goddard and Shoenfeld 2002). This fact
suggests that studying the speciﬁc sets of infections
that occur simultaneously in individual patients in
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immune diseases may provide crucial clues to the
origins of these diseases (Root-Bernstein and Hobbs
1992, Root-Bernstein and DeWitt 1994; Root-
Bernstein 1995). It is important to emphasize that
the theory does not predict that any random set of
concurrent infections increases risk of autoimmunity,
but only that concurrent, complementary infections
increase the risk of autoimmunity.
Again, some existing data suggest that this predic-
tion may be correct. For example, human immuno-
deﬁciency virus is know to bind to CD4-like regions
on sperm resulting in simultaneous immunological
processing of HIV and sperm antigens (reviewed in
Root-Bernstein and Hobbs 1993, Root-Bernstein and
Dewitt 1995). The result is induction of lympho-
cytotoxic autoantibodies that cross-react with sperm
(Sonnabend 1989; reviewed in Root-Bernstein and
Dewitt 1995). Similarly, in a study of people with
AIDS, only those with active cytomegalovirus
infection combined with active mycobacterial infec-
tion developed demyelinating autoimmunity (Root-
Bernstein 1991a). No other infection, or group of
infections, correlated with demyelinating autoimmu-
nity. This correlation between demyelinating auto-
immunity and combined CMV-mycobacterial
infections is also observed in people with transplants
and those on other forms of immunosuppressive
therapies. Notably, CMV is known to have signiﬁcant
homologies with myelin basic protein, and myco-
bacteria are, of course, a component of Freund’s
complete adjuvant, suggesting that AIDS-associated
demyelinization may truly be a form of human EAE.
This possibility is testable by combining myelin-like
CMV antigens with mycobacterial antigens to deter-
mine if a demyelinating animal model can be created.
The theory also makes a highly unusual prediction
that either antigen alone can be used to vaccinate
against the particular autoimmune disease that it can
induce in the presence of its complement (Figure 2).
This fact has been amply demonstrated in animal
models such as EAE in which either myelin basic
protein or mycobacterial adjuvant inoculated several
days to weeks prior to their mixture prevents EAE
induction (reviewed in Westall and Root-Bernstein
1983a,b, 1986, Root-Bernstein 1991b). Two, non-
exclusive explanations exist for such prevention based
on the complementary antigen theory. One expla-
nation is that by introducing one antigen, the
complementary antibody or T-cell clone is activated
and it proliferates. Since this antibody or T-cell clone
is, de facto, “self”, and since it is characterized by
being stereochemically complementary to the antigen,
this “self” determinant is the stereochemical comple-
ment to the antigen. Thus, when a mixture of the
antigen with its complement stimulates the immune
system, instead of provoking an autoimmune
response, the immune system will recognize the
complementary antigen as being “self” and fail to
produce an immune response to it. As with the general
theory, this speciﬁc explanation is also compatible
with Jerne’s network theory of immune system
regulation.
At the same time, another process may also be at
work that prevents induction of autoimmunity
following vaccination with a single antigen (Figure 2)
(reviewed in Westall and Root-Bernstein 1983a,b,
1986, Root-Bernstein 1991b). By the time the
complementary mixture stimulates the immune
system, the immunological response to the vaccinating
antigen will already be in place, or have a good head
start on the complementary response. Recall that
according to the complementary antigen theory, the
immunological response to the complementary anti-
gen (that is to say, the antibody or T-cells induced by
the complementary antigen) will mimic the vaccinat-
ing antigen. When the complementary antigen is
introduced into the immune system, any immune
response (antibody or T-cell) provoked by this
complementary antigen will be attacked by a more
mature, pre-existing set of antibodies or T-cells. Sheer
numbers dictate that the established or pre-existing
immune response will eliminate any complementary
immune response induced later. Again, this expla-
nation is consistent with Jerne’s network theory.
The suppression of an already-existing autoimmune
disease by one of the antigens used to induce that
disease can be explained by a similar process
(Figure 3). Again, such suppression has been
demonstrated for several animal models of auto-
immunity (reviewed in Westall and Root-Bernstein
1983a,b, 1986, Root-Bernstein 1991b, see also Root-
Bernstein et al. 1986). In EAE, for e.g., myelin basic
protein can suppress the disease and so can
mycobacterial antigens. Assuming that autoimmunity
will only exist if there is a relative balance or dynamic
Figure 2. Schematic model of prevention according to the
complementary antigen theory of autoimmunity. If a host
processes one (a) of a pair of complementary antigens signiﬁcantly
prior to the other, then the initial antigen induces its complementary
antibody (or T-cell response) ﬁrst (b). When the second,
complementary antigen is introduced to the immune system (c),
it mimics the antibody (or T-cell) response already in place within
the immune system. This existing immune response either prevents
the formation of the an immune response to the complementary
antigenbecause this antigen is recognized as “self”, or, if an immune
response is triggered, it will be eliminated by the pre-existing, initial
antibody (or T-cell).
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the complementary antigens, it follows that anything
that preferentially decreases one immune response, or
preferentially increases one response, will destroy the
balance, tipping the civil war in favor of one
immunological response or the other. Inoculating
large amounts of one causative agent into an organism
with a complementary antigen-induced disease will
induce a larger immune response to that antigen,
allowing the immunological response to it to over-
whelm the complementary immune response. Once a
single immune response dominates the regulatory
system, then the “self–nonself” distinction becomes
unambiguous again and the autoimmune process
ceases. For example, large amounts of myelin basic
protein, the so-called “encephalitogen” not only
suppress pre-existing EAE, but leave behind a very
robust anti-myelin immune response that no longer
attacks nerves. The current theory predicts that in this
case, the mycobacterial response will have dis-
appeared. Conversely, when mycobacterial antigens
are used to suppress EAE, the theory predicts that
anti-mycobacterial immunity will remain strong but
the response to myelin basic protein will disappear.
Similarly, if lipopolysaccharide is used to suppress
autoimmune thyroiditis, the LPS response should
remain strong following disease suppression, whereas
the thyroglobulin response should disappear. And in
adjuvant arthritis, heat shock protein suppression of
the disease should leave a strong HSP response while
eliminating the anti-collagen response.
Finally, the complementary antigen theory predicts
that the time-course of an autoimmune disease will
depend on three primary factors: (1) the relative
balance of immune responses provoked against the
pair of complementary antigens; (2) the relative
accessibility and concentrations of “self” antigens
that mimic the inducing antigens; and (3) the timing
of exposure to the complementary antigens. If the
mixture of complementary antigens is well-balanced
and provokes a well-balanced set of complementary
immune responses, and if each complementary
antigen mimics a “self” determinant that is readily
accessible to the immune system and present in
reasonably high concentrations, then one would
expect the resulting autoimmunity to be robust and
chronic. If, however, the mixture of antigens provokes
an unbalanced immune response, then one immune
response will eventually eliminate the complementary
one and the response will be acute. But even when a
well-balanced immune response is provoked by
complementary antigens, if only one of the antigens
mimics a “self” determinant, or only one of a pair of
mimics is readily accessible to the immune system,
then the autoimmune disease will be self-limiting as
one side of the immunological civil war slowly gains
dominance over the other. Thus, the theory explains
how varying the proportions of complementary
antigens and their respective “self” mimics can modify
the autoimmune disease process in ways that are seen
in both animal models and human cases. Finally, the
theory predicts that the antigens must be presented to
Figure 3. Schematic model of suppression of autoimmunity according to the complementary theory of autoimmunity. If autoimmunity
is induced by a pair of complementary antigens as in Figure 1 (a), and a large amount of one of the antigens is then presented to the
immune system (b), an increase in the immune response (antibody or T-cell) to that dose of antigen will occur. As a result of increasing one of
the complementary pair of immune responses at the expense of the other (c), the autoimmunity caused by the complementary immune
response will be blocked, and the enhanced immune response will eliminate the unenhanced one eliminating the autoimmune process and
returning the system to normal. Note that the enhanced immune response will remain, but since normal regulation will be restored (the
abrogation of the self–nonself distinction within the warring immune system eliminated), there will be no autoimmunity caused by the
remaining antibody.
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order to induce autoimmunity. If the antigens are
presented at signiﬁcantly different times, then auto-
immunity will be prevented by the mechanisms
described above.
Case study: Idiopathic thrombocytopenia
purpura
The real challenge to autoimmunity studies is, of
course, to elucidate the causes of autoimmunity in
human beings so that animal models can be set up that
mimic natural disease progression. This goal has so far
eluded investigators. Save, perhaps, for adjuvant
arthritis, which actually occurs in human patients
treated for cancer chemotherapy with mycobacterial
adjuvants, animal models of autoimmune diseases are
blatantly artiﬁcial, almost universally employing non-
infectious antigens such as vertebrate hormones or
proteins that are very unlikely to be involved in the
actual induction of human forms of disease (reviewed
in Cohen and Miller 1994; see also Oyaizu et al. 1988,
Musaji et al. 2004). The complementary antigen
theory of autoimmunity provides a novel strategy for
elucidating natural causes of human autoimmunity.
In some types of autoimmunity, the molecular
targets are well-enough deﬁned to provide strong clues
about the molecular complementarity that may be
involved. One such disease is the autoimmune blood
coagulation disease ITP, in which the primary
molecular targets of autoantibodies are known to
be platetelet glycoprotein 1b (pgp 1b) and von
Willebrand’s factor (VWF, or factor IX) (Kahane
et al. 1981, He et al. 1994, 1995, Hou et al. 1997,
Wadenvik et al. 1998, Ste ´phan et al. 2000, McMillan
2003). Notably, pgp 1b binds to VWF during the
normal course of the blood coagulation cascade, and
the binding regions of each molecule for the other
have been reasonably well characterized: the A1
binding domain of the mature VWF glycoprotein
(Gly
479 to Pro
717) interacts with the Platelet gp Ib
Platelet gp Ib a-chain (His
1–Arg
293) (Titani et al.
1987, Vicente et al. 1988, Emsley et al. 1998, Cruz
et al. 2000, Shimizu et al. 2004).
Since the molecular targets of ITP are known, and
these targets are molecularly complementary, it is
possible to use homology searching to identify sets of
potentially complementary antigens within possible
infectious agents that might be causative agents. The
search for such complementary antigens is greatly
facilitated by the fact that epidemiological studies have
identiﬁed a narrow range of infectious agents that are
highly associated with onset of ITP. These include
HIV-1, the herpes viruses, including cytomegalovirus,
Streptococcus, Mycobacterium, rubella virus, varicella
virus and Helicobacter as some of the most documented
infectious agents linked to ITP (Kahane et al. 1981,
Van Spronsen and Breed 1996, Wright et al. 1996, Bar
Meir et al. 2000, Humblot et al. 2001, Candelli et al.
2003, Fisgin et al. 2003, Ichiche et al. 2003, Takahashi
et al. 2004). Notably, many reports document
concurrent infections with two or more of these agents
(e.g. Rahal et al. 1968, Hamner et al. 1996,
Kouwabunpat et al. 1999, Sakata et al. 1999).
Using these molecular and epidemiological clues in
concert, we set out to determine whether two of the
most common agents associated with ITP onset—
cytomegalovirus (CMV) and streptococcus (speciﬁ-
cally group A) contained antigens with signiﬁcant
homologies to the complementary binding regions of
pgp1b and VWF. We also tested antibodies against
pgp1b and VWF to see: (1) whether they were
complementary to each other, as would be predicted
by the molecular complementarity of their antigens;
(2) whether anyof the antibodies against the infectious
agents identiﬁed epidemiologically as related to ITP
were complementary to each other; (3) whether any of
the antibodies against infectious agents were comple-
mentary to pgp1b or VWF. The object of these studies
was to determine whether it was possible to identify a
set of complementary antigens that could give rise to a
set of complementary antibodies that have speciﬁcity
for the targets of ITP in human beings, pgp1b and
VWF. There is one further step to this process that we
have not yet attempted, which is the use of antigens
identiﬁed by this process to induce a novel animal
model of ITP for the purposes of studying methods for
prevention and treatment of ITP.
Materials and methods
Homology searches
Homology searches were conducted between various
GAS proteins and both VWF (Swiss-Prot ID:
P04275) and Platelet gp Iba (Swiss-Prot ID:
P07359), and between various CMV proteins and
both VWF and Platelet GP Iba. Pearson’s LALIGN
program from the FASTA sequence alignment
analysis program was employed for the homology
scans at the following EMBnet organization URL:
http://www.ch.embnet.org/software/LALIGN_form.
html (Pearson and Lipman 1988, Huang and Miller
1991). The following alignment parameters were
selected: “local” was selected for “Alignment
method”; “Scoring matrix” was left at “default”;
“Opening gap penalty” was set at “ 2 14”; and
“Extending gap penalty” was set at “ 2 4”. The
signiﬁcance of each homology was determined based
on a numerical scoring method as previously
described (Root-Bernstein and Hobbs 1992; 1993,
Root-Bernstein and Dobbelstein 2001, Root-Bern-
stein 2004, Root-Bernstein and Rallo 2004, Root-
Bernstein 2005a,b): brieﬂy, an identical amino acid
was assigned a score of one; conservative substitutions
were assigned a score of one-half; and a homology was
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(i.e. at least 50% homology within ten consecutive
amino acids) was attained. This degree of homology is
also considered to be signiﬁcant by other laboratories
(31–34). For the hypothesis under consideration,
special focus was directed towards the alignments that
yielded homologies within the VWF A1 binding
domain of the mature glycoprotein (Gly
479–Pro
717)
for Platelet gp Iba, and within the Platelet gp Iba
binding domain (His
1–Arg
293) for VWF (35–41)
since these constitute the complementary binding
regions of the two proteins.
Double-antibody (DA) ELISA
85 different combinations between viral–bacterial,
viral–host protein, and bacterial–host protein anti-
bodies were tested for complementarity using DA-
ELISA, a simple modiﬁcation of the standard direct
and indirect ELISAs in which an antibody is adsorbed
onto the microplate well instead of antigen (Root-
Bernstein 1995, Root-Bernstein and Dobbelstein
2001, Root-Bernstein and Rallo 2004, Root-Bernstein
2004, Root-Bernstein 2005a,b). The strength of
binding between the two antibodies can be deter-
mined by serially diluting the antibody to be adsorbed
onto the solid phase, and then adding a second
antibody (preferably enzyme-conjugated) at a con-
stant concentration. If the second antibody is not
enzyme-conjugated, then an appropriate enzyme-
conjugated anti-IgG that is speciﬁc for the second
antibody is then added. The 21 viral, bacterial, and
human antibodies tested for complementarities are
speciﬁed in Table I.
Brieﬂy, serially diluted (PBS pH 7.4) antibody
(1mg/ml) to be adsorbed onto the microplate well was
added (100ml/well) to round-bottom 96-well micro-
plates (Costar) and incubated for at least 2h with
agitation at room temperature. Following adsorption,
wells were washed with a manual plate washer
(Biotrak) with 0.1% Tween-20 solution. Wells were
then blocked with saturated polyvinyl alcohol (PVA)
solution (200ml/well) and incubated for 1h. Follow-
ing blocking and washing, second antibody was added
(100ml/well) and incubated for 1h. If necessary,
appropriate anti-IgG was then added (100ml/well)
and incubated for 1h. Following incubation and
washing, ABTS (Chemicon International, Inc-Teme-
cula, CA) was then added (100ml/well) for color
development and the reaction stopped after 20–
30min. All washings were done 3 £ and all
experiments were performed in triplicate. Absor-
bances were read at 405nm with a SpectraMax 340
spectrophotometer (Molecular Devices-Sunnyvale,
CA). Non-speciﬁc binding of second antibody was
determined by coating wells with PVA only and then
subtracting this absorbance from the absorbances of
experimental wells. Data was analyzed with Soft-
maxePro and graphed with Excel.
Double-(monoclonal) antibody ELISA
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complementarity between certain polyclonal anti-
bodies (PABs), we further modiﬁed the DA-ELISA
described above in an effort to determine if the
complementarities could be identiﬁed to the level of
monoclonal speciﬁcity between MAB £ Platelet gp Ib
and the various CMV MABs (IEA, EA, SLA, gpB, gp
gH, 65kDa). Since MABs are not manufactured in
enzyme-conjugated form, such an ELISA derivation
would involve adsorption of one MAB onto the solid
phase, blockage with PVA, addition of the second
MAB (to be tested for its complementarity to the ﬁrst
MAB), and ﬁnally addition of anti-Ms IgG-HRP.
However, this procedure would yield misleading
results since one would not be able to discern how
much of the binding activity is attributable to binding
between the ﬁrst and second MAB, to binding
between the ﬁrst MAB and anti-Ms IgG-HRP, or to
binding between the second MAB and anti-Ms IgG-
HRP. To determine if these distinctions could be
achieved, three different binding assays (ie. three
different assays for each MAB-to-MAB combination)
were conducted simultaneously (preferably all on a
single 96-well microplate). To our knowledge, such an
ELISA derivation has not been reported by other
investigators.
Assay 1: serially diluted (PBS pH 7.4) MAB £
CMV (1mg/ml) to be adsorbed onto the microplate
well was added (100ml/well) to round-bottom 96-well
microplates (Costar) and incubated for at least 2h
with agitation at room temperature. Following
adsorption, wells were washed with a manual plate
washer (Biotrak) with 0.1% Tween-20 solution. Wells
were then blocked with saturated PVA solution
(200ml/well) and incubated for 1h. Following block-
ing and washing, MAB £ Platelet gp Ib at constant
concentration was added (100ml/well) and incubated
for 1h. Following incubation and washing, anti-Ms
IgG-HRP was then added (100ml/well) and incubated
for 1h.
Assay 2 (assessment of binding between MAB £
CMV and anti-Ms IgG-HRP): serially diluted (PBS
pH 7.4) MAB £ CMV (1mg/ml at the same dilution
as in Assay 1) to be adsorbed onto the microplate well
was added (100ml/well) to round-bottom 96-well
microplates (Costar) and incubated for at least 2h
with agitation at room temperature. Following
adsorption, wells were washed with a manual plate
washer (Biotrak) with 0.1% Tween-20 solution. Wells
were then blocked with saturated PVA solution
(200ml/well) and incubated for 1h. Following block-
ing and washing, anti-Ms IgG-HRP at the same
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(100ml/well) and incubated for 1h.
Following incubation and washing after addition of
anti-Ms IgG-HRP to all assays, ABTS (Chemicon)
was added for color development to all three assays
simultaneously, and absorbances were also sub-
sequently read for all three assays simultaneously. All
washings were done 3 £ and all assays were
performed in triplicate. Absorbances were read at
405nm with a SpectraMax 340 spectrophotometer
(Molecular Devices). Non-speciﬁc binding was
determined by coating wells with PVA only and then
subtracting this absorbance from the absorbances of
experimental wells. Data was analyzed with Soft-
maxePro and graphed with Excel.
Results
Homology searching demonstrates that both GAS and
CMV have multiple, statistically signiﬁcant,
sequences homologous with both regions of VWF
and pgp1b that are associated with the binding of
VWF to pgp1b (Tables I–IV). Such numerous and
signiﬁcant CMV and GAS homologous regions are
not found to other human proteins such as the insulin
receptor and glucagon receptor (data not shown) or
Table I. Platelet glycoprotein 1b sequence homologies with group A streptococcus proteins. The glycoprotein region used for homology
searching is that associated with von Willebrand factor binding (see text).
R. Root-Bernstein & J. Couturier 56between VWF and pgp1b and other viruses such as
the coxsakie viruses (data not shown).
Table V summarizes the double antibody ELISA
studies performed thus far. A selection of cases are
shown in Figures 4–11. Table one demonstrates that
all of the basic criteria required by the multiple antigen
theory of autoimmunity are satisﬁed. Antibodies
against VWF bind to antibodies against pgp1b
(Figures 4 and 5) demonstrating that the known
complementarity between the antigens is reﬂected in
the antibodies they elicit. Antibodies against CMV
bind to antibodies against GAS (Figure 6), demon-
strating that these antibodies can be complementary
(or idiotype–antiidiotype). GAS antibodies bind to
VWF antibodies (Figure 7), demonstrating that GAS
and VWF are complementary. CMV antibodies bind
to pgp1b antibodies (Figure 8), demonstrating that
these antibodies are also complementary. However,
some CMV antibodies also bind to VWF antibodies
(Figures 9 and 10), and some GAS antibodies also
bind to pgp1b antibodies (Figure 11).
Discussion
Homology searching reveals that both CMVand GAS
contain multiple antigens that may mimic both VWF
and platelet glycoprotein 1b within the regions of
VWF and pgp1b that are associated with their mutual
binding. Thus, homology results suggest that CMV
and GAS may elicit complementary antibodies in
Table II. Von Willebrand factor (factor IX) sequence homologies with cytomegalovirus proteins. The von Willebrand factor region used for
homology searching is that associated with platelet glycoprotein binding (see text).
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complementary antigen theory of autoimmunity.
The results of double antibody ELISAs conﬁrm the
homology data predictions that CMV and GAS
antigens are homologous to VWF and pgp1b antigens.
VWF antibodies are complementary to platelet
glycoprotein 1b antibodies as would be expected
from the known complementarity of their antigenic
sequences (Figures 4 and 5). CMV antibodies are
complementary to GAS antibodies, again as predicted
from the homology data and from theory (Figure 6).
Again in accord with the homology results, there
appear to be multiple sets of CMV antibodies with
different speciﬁcities that are complementary to GAS
antibodies. Some GAS antibodies are complementary
to both VWF and pgp1b antibodies (Figures 7 and
11), and some CMVantibodies are complementary to
both VWF and pgp1b (Figures 8–10). Thus, there are
two possible ways in which CMV and GAS may
interact. CMV antigens may mimic VWF antigens
while GAS antigens mimic pgp1b; or CMV antigens
may mimic pgp1b antigens while GAS antigens mimic
VWF antigens; or both may occur simultaneously.
Unexpectedly, these results also suggest that GAS
may contain a signiﬁcant number of complementary
antigens within itself that mimic both VWFand pgp1b
so that it is capable of satisfying the complementary
antigen theory of autoimmunity by itself. Similary for
CMV, we have thus far, however, found no set of GAS
antibodies that bind to each other, nor any set of CMV
antibodies that are complementary, so the possibility
of a complex agent inducing sets of complementary
antibodies remains possible but conjectural.
In sum, our data satisfy the theoretical predictions
made about possible induction of ITP by the
complementary antigen theory of autoimmunity using
antigenic sequences and antibodies induced bya pairof
infectiousagentsbothassociatedepidemiologicallywith
Table III. Von Willebrand factor (factor IX) sequence homologies with group A streptococcus proteins. The von Willebrand factor region
used for homology searching is that associated with platelet glycoprotein binding (see text).
R. Root-Bernstein & J. Couturier 58risk for ITP. Several steps clearly remain to be satisﬁed
beforethe theory can beconsideredvalidated,however,
and these include demonstrations that the CMV and
GAS antibodies identiﬁed here actually recognized ITP
related antigens (VWF and platelet glycoproteins); that
the CMV and GAS antigens are themselves comp-
lementary (i.e. bind to each other) as do the proteins
they mimic (VWF and pgp1b); and most importantly
thatacombinationofsuchantigensis,infact,capableof
inducingITPexperimentallyinananimalmodel.Much
Table IV. Platelet glycoprotein 1b sequence homologies with cytomegalovirus proteins. The glycoprotein region used for homology
searching is that associated with von Willebrand factor binding (see text).
Table V. Summary of double antibody ELISA experiments used to test whether for possible idiotype–antiidiotype relationships between
group A streptococcus antibodies, cytomegalovirus antibodies, platelet glycoprotein antibodies, and von Willebrand factor antibodies. See
ﬁgures for examples of positive (þ) results. Blanks indicate that the experiment was not done.
Double antibody elisas
(1)
Gt £ GAS
(2)
Rbt £ GAS
(3) G.
pig £ CMV
(4)
Gt £ CMV
(11)
Gt £ VWF
(12)
Shp £ VWF
(13)
Gt £ Plt gp Ib
(14)
MAB £ Plt gp Ib
(1) Gt £ GAS þþ 2 þ 2
(2) Rbt £ GAS 22 2 2
(3) G. pig £ CMV þ 22 2 þþ
(4) Gt £ CMV 22 22 2 2
(5) MAB £ CMV IEA 22 22
(6) MAB £ CMV EA 22 22 þ 2
(7) MAB £ CMV gpB 22 22 þ 2
(8) MAB £ CMV gp gH 22 22 þ
(9) MAB £ CMV SLA 22 22 þ 2
(10) MAB £ CMV 65kD 22 22 þ
(11) Gt £ VWF þ 222 þ 2
(12) Shp £ VWF 22 þ 2 þþ
(13) Gt £ Plt gp Ib þ 22 þþ
(14) MAB £ Plt gp Ib 2 þ 22 þ
(15) Shp £ Plt gp IIb/IIIa 2 þ 22 þ
(16) MAB £ EBV 2
(17) Gt £ HIV 2 1 22 2 2 2
(18) Gt £ HSV-1 22 2 2 2
(19) Shp £ HSV-2 22 2 2 2
(20) Gt £ HBsAg 22 2 2 2
(21) Rbt £ M. tuberculosis 22 2 2 2
Complementary antigens in autoimmunity 59work clearly remains to be done to test the theory that
CMVand GAS may interact to produce ITP.
We also caution that the choice of this particular
pair of infectious agents does not imply that other
pairs of agents cannot be involved in the induction of
ITP. ITP may have many causes, so that combinations
of staphylococci with rubella or varicella, or helico-
bacter with some herpes virus might also be implicated
in some forms of ITP. Indeed, there is no reason to
think that ITP need have one cause, nor one
mechanism.
Antisense peptides as complementary antigens
Pendergraft et al. (2004) have recently described a
human form of autoimmunity triggered by cPR-3
(105–201), a protein complementary to human
autoantigen proteinase-3. Their discovery has signiﬁ-
cantly raised interest in the possibility that comp-
lementary antigens play a role in the induction of
autoimmunity (Shoenfeld 2004, McGuire and
Holmes 2005). There are, however, a number of
ambiguities and technical difﬁculties associated with
their work that need to be addressed in the context of
the theory being proposed here.
To begin with, Pendergraft et al. (2004) have
adopted a deﬁnition of complementarity that is
signiﬁcantly more limited than that employed here.
The deﬁnition of complementarity employed here is
that antigens must be capable of stereospeciﬁc binding
to each other and that stereospeciﬁc binding must
be manifested by the induction of pairs of comple-
mentary antibodies (or T-cells) that act like idiotype–
antiidiotype pairs. Pendergraft et al. (2004, 2005), in
Antibody Manufacturer Catalog No.
(1) Goat £ Group A Streptococcus, HRP Biodesign International, Kennebunkport, ME, USA B65150P
(2) Rabbit £ Group A Streptococcus Biodesign International B83601R
(3) Guinea pig £ Cytomegalovirus Biodesign International B47821P
(4) Goat £ Cytomegalovirus, virions, HRP Biodesign International B65273G
(5) MAB £ Cytomegalovirus, pp72 immediate early antigen Biodesign International C8A022M
(6) MAB £ Cytomegalovirus, 65kDa early antigen Biodesign International C86314M
(7) MAB £ Cytomegalovirus, Glycoprotein B Biodesign International C65826M
(8) MAB £ Cytomegalovirus, Glycoprotein gH Biodesign International C65861M
(9) MAB £ Cytomegalovirus, 45kDa Structural late antigen Biodesign International C65879M
(10) MAB £ Cytomegalovirus, 65kD Late major matrix protein Biodesign International C65083M
(11) Goat £ von Willebrand Factor, HRP Cedarlane Laboratories LTD, Ontario, Canada CL20175HP
(12) Sheep £ von Willebrand Factor Biodesign International K90054C
(13) Goat £ Platelet gp Ib Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA sc-7071
(14) MAB £ Platelet gp Ib Biomeda Corporation, Foster City, CA, USA V1103
(15) Sheep £ Platelet gp IIb/IIIa Cedarlane Laboratories LTD CL20069A
(16) MAB £ Epstein-Barr virus Biodesign International C65221M
(17) Goat £ HIV-1, HRP Biodesign International B65873G
(18) Goat £ HSV-1, HRP Biodesign International B65134G
(19) Sheep £ HSV-2, HRP Biodesign International B651245
(20) Goat £ Hepatitis B surface antigens, (HBsAg), (ad/ay), HRP Biodesign International B65804P
(21) Rabbit £ M. tuberculosis, HRP Biodesign International B65601C
Figure 4. Double antibody ELISA.
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Figure 5. Double antibody ELISA.
R. Root-Bernstein & J. Couturier 60contrast, have deﬁned complementarity in terms of
Blalock’s concept of antisense proteins. In essence,
Blalock has proposed that if each chain of double-
stranded DNA could be translated into a protein, the
resulting proteinswould have an antisense relationship
equivalent to the antisense relationship of the original
DNA chains or their respective RNAs (Blalock and
Smith 1984, Tropsha et al. 1992). These antisense
proteins, or their peptide fragments, would bind to
each other, just as the antisense strands of DNA or
RNA bind to each other. The physicochemical basis of
this protein–protein binding is hydropathic comple-
mentarity, where hydropathy is a complex measure of
hydrophilicity/hydrophobicity, side chain size, etc.
There are two major problems with applying antisense
protein concepts to autoimmunity, one involving
intrinsic problems with Blalock’s concept, the other
involving ambiguities in the way that the concept is
being applied by Pendergraft et al. (2004, 2005).
The problem with Blalock’s concept of antisense
proteins is that there is almost no physicochemical
data demonstrating that proteins derived from
complementary chains of DNA are chemically
complementary, while there are many physicochem-
ical studies that show that such proteins do not bind
to each other (reviewed in Root-Bernstein and
Holsworth 1998, Siemion et al. 2004). There is little
evidence that such antisense proteins induce comp-
lementary antibodies that act like idiotype–antiidio-
type pairs and much that demonstrates failure to do
so. And there is an alternative theory of antisense
peptides, in which the complementary strands of
Figure 6. Double antibody ELISA.
Figure 7. Double antibody ELISA.
Figure 8. Double antibody ELISA.
Figure 9. Double antibody ELISA.
Complementary antigens in autoimmunity 61DNA are read in parallel (that is, one chain is read
“backwards” from the other) for which there is
signiﬁcant data demonstrating the production of
complementary proteins, and which can explain
most of the supposed data for Blalock’s hypothesis
(Root-Bernstein and Holsworth 1998, Siemion et al.
2004). Thus, it is not clear that Pendergraft’s et al.
(2004, 2005) demonstration that their proteins are
“complementary” according to Blalock’s criteria has
any meaning in terms of whether the proteins would
bind to each other or produce complementary
antibodies. These are points that need to be
experimentally demonstrated.
More importantly, none of the cases of antigen or
antibody complementarity described in this paper
satisfy the Blalock criteria. VWF and pgp1b do
not appear to bind to each other according to
hydropathic complementarity (data not shown). We
have previously demonstrated that hydropathic com-
plementarity cannot explain insulin–glucagon com-
plementarity, nor the ability of these proteins to
self-aggregate (Root-Bernstein 2005b). And there is
clearly no application of the antisense concept to the
interaction of myelin basic protein with MDP or other
bacterial cell-wall derived adjuvants, which are
primarily polysaccharide based. Thus, at the very
least,theproposalthatantisensepeptides,hydropathic
complementarity, or Blalock’s concepts are at the root
of autoimmune processes must be regarded as being of
limited value.
There also appears to be some ambiguity as to how
the concept of complementarity is being applied by
Pendergraft et al. (2004, 2005), and by those writing
about their ﬁndings. Pendergraft et al. (2004) write
that, “The theory proposes that the inciting immuno-
gen that elicits a cascade of immunological events is
not the self-antigen (the autoantigen) or its mimic but
rather a protein that is complementary...” This
proposal seems to put emphasis on the complemen-
tary protein as the single agent necessary to induce
autoimmunity and is not, therefore, equivalent to the
theory of complementary antigens proposed here,
which requires a pair of complementary antigens to
break self-tolerance, Pendergraft’s mechanism
appears to be much more similar to Plotz’s theory
that antiidiotype antibodies are the cause of auto-
immunity. In Plotz’s (1983) theory, viral capsid
proteins use host cellular receptors to infect cells.
The host responds by making antibodies to the capsid
proteins. These anti-capsid proteins mimic the
binding speciﬁcity of the cellular receptors.
If antiidiotype antibodies are produced to these anti-
capsid antibodies, then these will mimic the speciﬁ-
cities of the viral capsid proteins themselves, and
attack the host cellular receptors. This scenario seems
to be very similar to Pendergraft et al.’s theory that an
antisense peptide will induce antibodies that in turn
evoke antisense antibodies that become autoreactive.
On the other hand, McGuire and Holmes (2005)
have clearly interpreted the Pendergraft et al. data in a
manner that makes it much more similar to the theory
proposed here. McGuire and Holmes argue that each
protein generated by each strand of DNA will result in
an antigen that induces an appropriate antibody. They
assume that the antisense proteins encoded by
antisense genes will be antigenically complementary
and that the result will be antibodies that act like
idiotype–antiidiotype pairs. This is a pretty story, but
one for which even their references provide no
substance. We are not, therefore, convinced that the
application of antisense peptides and hydropathic
complementarity to autoimmune research will do
anything more than confuse thinking about how
properly to apply the concept of molecular comple-
mentarity to immunology.
Rethinking Koch’s postulates for autoimmune diseases
In concluding, it should be noted that the complemen-
tary antigen theory of autoimmunity is incompatible
Figure 10. Double antibody ELISA.
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Figure 11. Double antibody ELISA.
R. Root-Bernstein & J. Couturier 62with a strict reading of Koch’s postulates for the
identiﬁcation of the cause of disease (Root-Bernstein
1991b). In Koch’s model, diseases are caused by single
agents. Disease causation can be established by:
isolating in pure culture a single agent from a diseased
organism; inoculating the pure agent into a healthy
organism; observing the disease develop in the
previously healthy organism; and reisolating the
disease-associated agent from the now ill organism.
The complementary antigen theory of autoimmunity
predictsthatKoch’spostulateswillnotyieldthecauseof
any autoimmune disease since no single antigen will be
capable of inducing an autoimmune disease, and it will
be a rare phenomenon for a single infectious agent to
carry the requisite complementary set of antigens.
A revised set of postulates are needed to test the
complementary antigen theory: two or more puriﬁed
agentsmustbeassociatedwiththeautoimmunedisease;
none of the puriﬁed agents will able to induce the
autoimmunity individually; autoimmunity will only be
induced with a speciﬁc combination of the puriﬁed
disease-associated agents. It is, of course, likely that
none of the agents will be present by the time the
autoimmunity is diagnosed, as the immune system may
very well have eliminated the agents prior to targeting
the tissues or organs of the organism itself. Thus,
evidence of active immunity may need to replace
isolation of the disease agents themselves in the
determination of what agents are most likely correlated
withanyparticularformofautoimmunity.Inaddition,it
must be stressed that only speciﬁc pairs of puriﬁed
agents (such as CMV with mycobacteria), both present
simultaneously are predicted to be associated with
autoimmunity; encountering one agent signiﬁcantly
prior to the other will lead to protection against
autoimmunity. An equally important point to stress is
that random sets of infections, such as most people
encounter throughouttheirlives,areunlikelytocontain
thenecessarycomplementaryantigensandwillnotlead
toautoimmunity. Itisnotthefactthatcombinedagents
are encountered by the immune system that leads to
autoimmunity but the fact that a speciﬁc pair of agents
that are related by molecular complementarity are
encountered simultaneously by the immune system.
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